[1] |
. Cell Metab,2019,29(5):1028-1044.
|
[2] |
Cromby J,Chung E,Papadopoulos D,et al. Reviewing the epigenetics of schizophrenia[J]. J Ment Heal,2019,28(1):71-79.
|
[3] |
Duruisseaux M,Esteller M. Lung cancer epigenetics:from knowledge to applications[J]. Semin Cancer Biol,2018,51:116-128.
|
[4] |
Eckschlager T,Plch J,Stiborova M,et al. Histone deacetylase inhibitors as anticancer drugs[J]. Int J Mol Sci,2017,18(7):1414.
|
[5] |
Jones PA,Issa JPJ,Baylin S. Targeting the cancer epigenome for therapy[J]. Nat Rev Genet,2016,17(10):630-641.
|
[6] |
Jones PA,Baylin SB. The epigenomics of cancer[J]. Cell,2007,128(4):683-692.
|
[7] |
Berger SL,Kouzarides T,Shiekhattar R,et al. An operational definition of epigenetics[J]. Genes Dev,2009,23(7):781-783.
|
[8] |
Sheikhpour M,Maleki M,Ebrahimi Vargoorani M,et al. A review of epigenetic changes in asthma:methylation and acetylation[J]. Clin Epigenetics,2021,13(1):65.
|
[9] |
Hyun K,Jeon J,Park K,et al. Writing,erasing and reading histone lysine methylations[J]. Exp Mol Med,2017,49(4):e324.
|
[10] |
Kaniskan HU,Martini ML,Jin J. Inhibitors of protein methyltransferases and demethylases[J]. Chem Rev,2018,118(3):989-1068.
|
[11] |
Ruthenburg AJ,Allis CD,Wysocka J. Methylation of lysine 4 on histone H3:intricacy of writing and reading a single epigenetic mark[J]. Mol Cell,2007,25(1):15-30.
|
[12] |
Guenther MG,Jenner RG,Chevalier B,et al. Global and hox-specific roles for the MLL1 methyltransferase[J]. Proc Natl Acad Sci U S A,2005,102(24):8603-8608.
|
[13] |
Dou Y,Milne TA,Tackett AJ,et al. Physical association and coordinate function of the H3K4 methyltransferase MLL1 and the H4K16 acetyltransferase MOF[J]. Cell,2005,121(6):873-885.
|
[14] |
Daigle SR,Olhava EJ,Therkelsen CA,et al. Potent inhibition of dot1l as treatment of MLL-fusion leukemia[J]. Blood,2013,122(6):1017-1025.
|
[15] |
Grembecka J,He S,Shi A,et al. Menin-MLL1 inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia[J]. Nat Chem Biol,2012,8(3):277-284.
|
[16] |
Hess JL. MLL:a histone methyltransferase disrupted in leukemia[J]. Trends Mol Med,2004,10(10):500-507.
|
[17] |
Glaser S,Schaft J,Lubitz S,et al. Multiple epigenetic maintenance factors implicated by the loss of MLL2 in mouse development[J]. Development,2006,133(8):1423-1432.
|
[18] |
Butler LH,Slany R,Cui X,et al. The HRX proto-oncogene product is widely expressed in human tissues and localizes to nuclear structures[J]. Blood,1997,89(9):3361-3370.
|
[19] |
Tkachuk DC,Kohler S,Cleary ML. Involvement of a homolog of drosophila trithorax by 11q23 chromosomal translocations in acute leukemias[J]. Cell,1992,71(4):691-700.
|
[20] |
Cosgrove MS,Patel A. Mixed lineage leukemia:a structure-function perspective of the MLL1 protein[J]. FEBS J,2010,277(8):1832-1842.
|
[21] |
Gu Y,Nakamura T,Alder H,et al. The T(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene,related to drosophila trithorax,to the AF-4 gene[J]. Cell,1992,71(4):701-708.
|
[22] |
Yokoyama A,Kitabayashi I,Ayton PM,et al. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties[J]. Blood,2002,100(10):3710-3718.
|
[23] |
Argiropoulos B,Humphries RK. Hox genes in hematopoiesis and leukemogenesis[J]. Oncogene,2007,26(47):6766-6676.
|
[24] |
Dou Y,Hess JL. Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia[J]. Int J Hematol,2008,87(1):10-18.
|
[25] |
Milne TA,Kim J,Wang GG,et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the hoxa9 locus in leukemogenesis[J]. Mol Cell,2010,38(6):853-863.
|
[26] |
Chang PY,Hom RA,Musselman CA,et al. Binding of the MLL1 PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription[J]. J Mol Biol,2010,400(2):137-144.
|
[27] |
Mcmahon KA,Hiew SY,Hadjur S,et al. MLL has a critical role in fetal and adult hematopoietic stem cell self-renewal[J]. Cell Stem Cell,2007,1(3):338-345.
|
[28] |
Ansari KI,Kasiri S,Mandal SS. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo[J]. Oncogene,2013,32(28):3359-3370.
|
[29] |
Scharf S,Zech J,Bursen A,et al. Transcription linked to recombination:a gene-internal promoter coincides with the recombination hot spot Ⅱ of the human MLL gene[J]. Oncogene,2007,26(10):1361-1371.
|
[30] |
Yu BD,Hanson RD,Hess JL,et al. MLL,a mammalian trithorax-group gene,functions as a transcriptional maintenance factor in morphogenesis[J]. Proc Natl Acad Sci U S A,1998,95(18):10632-10636.
|
[31] |
Winters AC,Bernt KM. MLL-rearranged leukemias-an update on science and clinical approaches[J]. Front Pediatr,2017,5:4.
|
[32] |
Ayton PM,Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins[J]. Oncogene,2001,20(40):5695-5707.
|
[33] |
Meyer C,Kowarz E,Hofmann J,et al. New insights to the MLL recombinome of acute leukemias[J]. Leukemia,2009,23(8):1490-1499.
|
[34] |
Luo Z,Lin C,Shilatifard A. The super elongation complex(SEC) family in transcriptional control[J]. Nat Rev Mol Cell Biol,2012,13(9):543-547.
|
[35] |
Nguyen AT,Zhang Y. The diverse functions of Dot1 and H3K79 methylation[J]. Genes Dev,2011,25(13):1345-1358.
|
[36] |
Muntean AG,Hess JL. The pathogenesis of mixed-lineage leukemia[J]. Annu Rev Pathol,2012,7:283-301.
|
[37] |
Milne TA,Martin ME,Brock HW,et al. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus,promoting transcription and multiple histone modifications[J]. Cancer Res,2005,65(24):11367-11374.
|
[38] |
Thiel AT,Blessington P,Zou T,et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele[J]. Cancer Cell,2010,17(2):148-159.
|
[39] |
Wang QF,Wu G,Mi S,et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome[J]. Blood,2011,117(25):6895-6905.
|
[40] |
Dou Y,Milne TA,Ruthenburg AJ,et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components[J]. Nat Struct Mol Biol,2006,13(8):713-719.
|
[41] |
Patel A,Dharmarajan V,Vought VE,et al. On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1(MLL1) core complex[J]. J Biol Chem,2009,284(36):24242-24256.
|
[42] |
Karatas H,Townsend EC,Cao F,et al. High-affinity,small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction[J]. J Am Chem Soc,2013,135(2):669-682.
|
[43] |
Grebien F,Vedadi M,Getlik M,et al. Pharmacological targeting of the WDR5-MLL interaction in C/EBPα n-terminal leukemia[J]. Nat Chem Biol,2015,11(8):571-578.
|
[44] |
Odho Z,Southall SM,Wilson JR. Characterization of a novel WDR5-binding site that recruits RbBP5 through a conserved motif to enhance methylation of histone H3 lysine 4 by mixed lineage leukemia protein-1[J]. J Biol Chem,2010,285(43):32967-32976.
|
[45] |
Gregory GD,Vakoc CR,Rozovskaia T,et al. Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes[J]. Mol Cell Biol,2007,27(24):8466-8479.
|
[46] |
Chen Z,Yan CT,Dou Y,et al. The role of a newly identified SET domain-containing protein,SETD3,in oncogenesis[J]. Haematologica,2013,98(5):739-743.
|
[47] |
Wang F,Jeon KO,Salovich JM,et al. Discovery of potent 2-aryl-6,7-dihydro-5 h-pyrrolo[1,2-a]imidazoles as WDR5-win-site inhibitors using fragment-based methods and structure-based design[J]. J Med Chem,2018,61(13):5623-5642.
|
[48] |
Getlik M,Smil D,Zepeda-Vel??zquez C,et al. Structure-based optimization of a small molecule antagonist of the interaction between WD repeat-containing protein 5(WDR5) and mixed-lineage leukemia 1(MLL1)[J]. J Med Chem,2016,59(6):2478-2496.
|
[49] |
Zhang P,Lee H,Brunzelle JS,et al. The plasticity of WDR5 peptide-binding cleft enables the binding of the SET1 family of histone methyltransferases[J]. Nucleic Acids Res,2012,40(9):4237-4246.
|
[50] |
Patel A,Vought VE,Dharmarajan V,et al. A conserved arginine-containing motif crucial for the assembly and enzymatic activity of the mixed lineage leukemia protein-1 core complex[J]. J Biol Chem,2008,283(47):32162-32175.
|
[51] |
Karatas H,Townsend EC,Bernard D,et al. Analysis of the binding of mixed lineage leukemia 1(MLL1) and histone 3 peptides to WD repeat domain 5(WDR5) for the design of inhibitors of the MLL1-WDR5 interaction[J]. J Med Chem,2010,53(14):5179-5185.
|
[52] |
Cao F,Townsend EC,Karatas H,et al. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia[J]. Mol Cell,2014,53(2):247-261.
|
[53] |
Karatas H,Li Y,Liu L,et al. Discovery of a highly potent,cell-permeable macrocyclic peptidomimetic(MM-589) targeting the WD repeat domain 5 protein(WDR5)-mixed lineage leukemia(MLL) protein-protein interaction[J]. J. Med. Chem.,2017,60(12):4818-4839.
|
[54] |
Senisterra G,Wu H,Allali-Hassani A,et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5[J]. Biochem J,2013,449(1):151-159.
|
[55] |
Bolshan Y,Getlik M,Kuznetsova E,et al. Synthesis,optimization,and evaluation of novel small molecules as antagonists of WDR5-MLL interaction[J]. ACS Med Chem Lett,2013,4(3):353-357.
|
[56] |
Li DD,Chen WL,Xu XL,et al. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5[J]. Eur J Med Chem,2016,118:1-8.
|
[57] |
Chen WL,Chen X,Li DD,et al. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity[J]. Eur J Med Chem,2021,223:113677.
|
[58] |
Chen WL,Chen X,Li DD,et al. Discovery of DDO-2213 as a potent and orally bioavailable inhibitor of the WDR5-mixed lineage leukemia 1 protein-protein interaction for the treatment of MLL fusion leukemia[J]. J Med Chem,2021,64(12):8221-8245.
|
[59] |
Rima AA,Methvin I,Babu J,et al. Inhibitor of WDR5 protein-protein binding: WO2017147700A1[P]. 2017-09-08.
|
[60] |
Rima AA,Methvin I,Babu J,et al. Inhibitor of WDR5 protein-protein binding: WO2019046944A1[P]. 2019-03-04.
|
[61] |
Aho ER,Wang J,Gogliotti RD,et al. Displacement of WDR5 from chromatin by a WIN site inhibitor with picomolar affinity[J]. Cell Rep,2019,26(11):2916-2928.e13.
|
[62] |
Tian JH,Teuscher KB,Aho ER,et al. Discovery and structure-based optimization of potent and selective WD repeat domain 5(WDR5) inhibitors containing a dihydroisoquinolinone bicyclic core[J]. J Med Chem,2020,63(2):656-675.
|
[63] |
Albert L,Xu J,Wan RW,et al. Controlled inhibition of methyltransferases using photoswitchable peptidomimetics:towards an epigenetic regulation of leukemia[J]. Chem Sci,2017,8(6):4612-4618.
|
[64] |
Chen WL,Li DD,Wang ZH,et al. Design,synthesis,and initial evaluation of affinity-based small molecular probe for detection of WDR5[J]. Bioorg Chem,2018,76:380-385.
|
[65] |
Jian J,Dongxu L,Jing L,et al. Wd40 repeat domain protein 5(WDR5) degradation/destruction compound and method of use: WO2019246570A1[P]. 2019-12-26.
|
[66] |
Avdic V,Zhang P,Lanouette S,et al. Structural and biochemical insights into MLL1 core complex assembly[J]. Structure,2011,19(1):101-108.
|